172 related articles for article (PubMed ID: 37736724)
1. Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML.
Li H; Wang Y; Feng S; Chang K; Yu X; Yang F; Huang H; Wang Y; Li X; Guan F
Cell Commun Signal; 2023 Sep; 21(1):255. PubMed ID: 37736724
[TBL] [Abstract][Full Text] [Related]
2. Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs.
Li H; Wang Y; Yang F; Feng S; Chang K; Yu X; Guan F; Li X
Redox Biol; 2023 Nov; 67():102900. PubMed ID: 37748319
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
4. Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.
Tamura M; Yonezawa T; Liu X; Asada S; Hayashi Y; Fukuyama T; Tanaka Y; Kitamura T; Goyama S
Sci Rep; 2019 Jun; 9(1):8171. PubMed ID: 31160638
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.
Wang L; Zhang Q; Ye L; Ye X; Yang W; Zhang H; Zhou X; Ren Y; Ma L; Zhang X; Mei C; Xu G; Li K; Luo Y; Jiang L; Lin P; Zhu S; Lang W; Wang Y; Shen C; Han Y; Liu X; Yang H; Lu C; Sun J; Jin J; Tong H
Br J Cancer; 2023 Feb; 128(4):691-701. PubMed ID: 36482192
[TBL] [Abstract][Full Text] [Related]
7. DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
Casellas Román HL; Venugopal K; Feng Y; Shabashvili DE; Posada LM; Li J; Guryanova OA
Leuk Res; 2020 Jul; 94():106372. PubMed ID: 32445940
[No Abstract] [Full Text] [Related]
8. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Decitabine on Regulatory T Cells Relative Content in Peripheral Blood and Bone Marrow of Patients with Myelodysplastic Syndrome/Acute Myeloid Leukemia].
Hu R; Gao Y; Wen Y; Wu K; Duan C; Zeng Y; Shi MX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):36-42. PubMed ID: 35123601
[TBL] [Abstract][Full Text] [Related]
10. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
[TBL] [Abstract][Full Text] [Related]
11. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
12. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
13. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
14. Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
Zhao WH; Zeng QC; Huang BT; Li BS; Chen RL
Leuk Res; 2015 Apr; 39(4):424-8. PubMed ID: 25721158
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
16. Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes.
Kim S; Shin DY; Kim D; Oh S; Hong J; Kim I; Kim E
Cells; 2021 Dec; 10(12):. PubMed ID: 34944006
[TBL] [Abstract][Full Text] [Related]
17. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Huang L; Liu Z; Jiang H; Li L; Fu R
J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
[TBL] [Abstract][Full Text] [Related]
18. Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.
Li H; Wang Y; Pang X; Xie C; Deeg JH; Wang H; Wan T; Wu J; Guan F; Li X
Haematologica; 2020 Oct; 105(10):e502. PubMed ID: 33054092
[No Abstract] [Full Text] [Related]
19. Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia.
Feng X; Chen X; Nie S; Chang Y; Meng F; Zhou J; Mao C; Li T; Yan X; Huang J; Liu S; Gao Y; Xiao S
J Cancer Res Ther; 2019; 15(7):1471-1476. PubMed ID: 31939424
[TBL] [Abstract][Full Text] [Related]
20. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
